@article{984b7e470e73448db77e924794b9c34a,
title = "Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study: Journal of Geriatric Oncology",
abstract = "Background: Advanced age is associated with comorbidities and immune system impairment, which may influence the efficacy and tolerability of immune checkpoint inhibitors. There is evidence that anti-PD1 antibodies in advanced melanoma are equally effective in patients >65 years. However, data on patients >75 years are lacking as co-morbidities and logistics often exclude them from clinical trials. Methods: We retrospectively reviewed the clinical records of older patients with advanced melanoma undergoing any-line treatment with an anti-PD1 (nivolumab/pembrolizumab) to investigate its clinical effectiveness and toxicity in a real-life setting. Clinical response was assessed using RECIST criteria and toxicity was evaluated according to CTCAE 4.0. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and the Cox model was used to assess potential prognostic factors. Results: 174 patients were considered; 59.2% males, median age 79 years (range 75–93). The majority had a performance status of 0 and normal lactate dehydrogenase (LDH) levels (55.2% and 52.4%, respectively). 69.1% had multiple co-morbidities. 56.9% received nivolumab. 36.7% of cases showed an objective response and the disease control rate was 56.3%. Median OS was 17.2 months [95% CI: 8.87-not reached] and a better prognosis was observed for patients with normal LDH (p <.001) and lower performance status (p <.001). Treatment was well tolerated, only 11 patients experiencing severe (grade 3/4) toxicity. There were no treatment-related deaths. Adverse events were managed with corticosteroids and additional immunosuppressive agents were unnecessary. Conclusions: Anti-PD1 antibodies appear effective and well tolerated in older patients with advanced melanoma. {\textcopyright} 2020 Elsevier Inc.",
keywords = "Aging, Drug effects, Immunosenescence, Immunotherapy, Melanoma, Older patients, B Raf kinase, corticosteroid, lactate dehydrogenase, nivolumab, pembrolizumab, prednisone, Ras protein, aged, aging, anxiety, Article, BRAF gene, brain toxicity, cancer prognosis, chronic obstructive lung disease, comorbidity, comparative study, controlled study, death, diabetes mellitus, disease classification, drug cost, drug efficacy, drug safety, drug tolerability, exploratory research, female, follow up, gastrointestinal toxicity, gene mutation, health status, heart failure, human, hypertension, hypophysitis, information processing, Italian (citizen), Kaplan Meier method, kidney failure, liver failure, liver toxicity, lung toxicity, major clinical study, male, medical record, melanoma, metastatic melanoma, multicenter study, multivariate analysis, mutational analysis, nephrotoxicity, oncogene, oncogene ras, overall survival, prevalence, priority journal, progression free survival, proportional hazards model, retrospective study, skin disease, thyroiditis, treatment duration, treatment response, vascular disease, very elderly",
author = "L. Ridolfi and {De Rosa}, F. and E. Petracci and E.T. Tanda and E. Marra and J. Pigozzo and R. Marconcini and M. Guida and G.C.A. Cappellini and G. Gallizzi and M. Occelli and L. Pala and E. Gambale and M. Bersanelli and G. Galdo and A. Cortellini and F. Morgese and F. Zoratto and L.S. Stucci and S. Strippoli and M. Guidoboni and (IMI), {On behalf of the Italian Melanoma Intergroup}",
note = "Cited By :7 Export Date: 2 February 2021 Correspondence Address: Petracci, E.; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Italy; email: elisabetta.petracci@irst.emr.it Chemicals/CAS: lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; prednisone, 53-03-2 Funding text 1: The authors wish to thank Gr?inne Tierney and Cristiano Verna for editorial assistance. References: Yancik, R., Ries, L.A., Aging and cancer in America. Demographic and epidemiologic perspectives (2000) Hematol Oncol Clin North Am, 14, pp. 17-23. , https://doi.org/S0889-8588(05)70275-6, [ pii]; Provinciali, M., Immunosenescence and cancer vaccines (2009) Cancer Immunol Immunother, 58, pp. 1959-1967; Teig, N., Moses, D., Gieseler, S., Schauer, U., Age-related changes in human blood dendritic cell subpopulations (2002) Scand J Immunol, 55, pp. 453-457; Mazzola, P., Radhi, S., Mirandola, L., Annoni, G., Jenkins, M., Cobos, E., Aging, cancer, and cancer vaccines (2012) Immun Ageing, 9, p. 4; Korn, E.L., Liu, P.Y., Lee, S.J., Chapman, J.A.W., Niedzwiecki, D., Suman, V.J., Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials (2008) J Clin Oncol, 26, pp. 527-534; Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma (2015) J Clin Oncol, 33, pp. 1889-1894; Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Nivolumab in previously untreated melanoma without BRAF mutation (2015) N Engl J Med, 372, pp. 320-330; Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma (2015) N Engl J Med, 372, pp. 2006-2017; Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Overall survival with combined nivolumab and ipilimumab in advanced melanoma (2017) N Engl J Med, 377, pp. 1345-1356; Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C.L., Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018) Lancet Oncol, 19, pp. 1480-1492; Kendal, W.S., Dying with cancer: the influence of age, comorbidity, and cancer site (2008) Cancer, 112, pp. 1354-1362; Helissey, C., Vicier, C., Champiat, S., The development of immunotherapy in older adults: new treatments, new toxicities? (2016) J Geriatr Oncol, 7, pp. 325-333; Elias, R., Karantanos, T., Sira, E., Hartshorn, K.L., Immunotherapy comes of age: immune aging & checkpoint inhibitors (2017) J Geriatr Oncol, 8, pp. 229-235. , https://doi.org/S1879-4068(17)30027-9, []; Nishijima, T.F., Muss, H.B., Shachar, S.S., Moschos, S.J., Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis (2016) Cancer Treat Rev, 45, pp. 30-37; Sileni, V.C., Pigozzo, J., Ascierto, P.A., Grimaldi, A.M., Maio, M., Guardo, L., Efficacy and safety of ipilimumab in older patients patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) J Exp Clin Cancer Res, 33; Perier-Muzet, M., Gatt, E., Peron, J., Falandry, C., Amini-Adle, M., Thomas, L., Association of immunotherapy with overall survival in older patients patients with melanoma (2018) JAMA Dermatol, 154, pp. 82-87; Bastiaannet, E., Battisti, N., Loh, K.P., de Glas, N., Soto-Perez-de-Celis, E., Baldini, C., Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper (2019) J Geriatr Oncol, 10, pp. 389-397; Orimo, H., Ito, H., Suzuki, T., Araki, A., Hosoi, T., Sawabe, M., Reviewing the definition of “older patients” (2006) Geriatr Gerontol Int, 6, pp. 149-158; Santoni, G., Angleman, S., Welmer, A.K., Mangialasche, F., Marengoni, A., Fratiglioni, L., Age-related variation in health status after age 60 (2015) PLoS One, 10; Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale (1992) Psychiatry Res, 41, pp. 237-248; Extermann, M., Overcash, J., Lyman, G.H., Parr, J., Balducci, L., Comorbidity and functional status are independent in older cancer patients (1998) J Clin Oncol, 16, pp. 1582-1587; Lasithiotakis, K.G., Petrakis, I.E., Garbe, C., Cutaneous melanoma in the older patients: epidemiology prognosis and treatment (2010) Melanoma Res, 20, pp. 163-170; Pawelec, G., Lustgarten, J., Ruby, C., Gravekamp, C., Impact of aging on cancer immunity and immunotherapy (2009) Cancer Immunol Immunother, 58, pp. 1907-1908; Pawelec, G., Derhovanessian, E., Larbi, A., Immunosenescence and cancer (2010) J Geriatr Oncol, 1, pp. 20-26; Hurez, V., Padron, A.S., Svatek, R.S., Curiel, T.J., Considerations for successful cancer immunotherapy in aged hosts (2017) Clin Exp Immunol, 187, pp. 53-63; Singh, H., Beaver, J.A., Kim, G., Pazdur, R., Enrollment of older adults on oncology trials: an FDA perspective (2017) J Geriatr Oncol, 8, pp. 149-150. , https://doi.org/S1879-4068(16)30163-1, []; Ribas, A., Hamid, O., Daud, A., Hodi, F.S., Wolchok, J.D., Kefford, R., Association of pembrolizumab with tumor response and survival among patients with advanced melanoma (2016) JAMA, 315, pp. 1600-1609; Orloff, M., Melanoma immunotherapy in the older patients (2018) Curr Oncol Rep, 20, pp. 20-23",
year = "2020",
doi = "10.1016/j.jgo.2019.12.012",
language = "English",
volume = "11",
pages = "515--522",
journal = "J. Geriatr. Oncol.",
issn = "1879-4068",
publisher = "Elsevier Ltd",
number = "3",
}